Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Fireside Chat on August 10

<< Previous

Bullboard Posts

Next >>

Comment by LouisWon Aug 03, 2022 9:50pm

125 Views

Post# 34870054

RE:RE:RE:RE:RE:RE:RE:Fireside Chat on August 10

Agreed. Running the trial without SORT1 expression is also my consern. Immunomedics didnt evaluate the trop2 expression prior to the treatment since they claimed that 88% of the patients expressing Trop2 based on the TMA data. However, Her2 expreesion level was confirmed prior to treatment of Trastuzumab Emtansine. Maybe TH will do IHC staining prior to treatment in the larger trial. They cannot let the probability determine the fate of the trial.

<< Previous

Bullboard Posts

Next >>

BMO evolves InvestorLine with enhanced tools for options trading